Arca biopharma, inc. (ABIO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-1,320

-1,226

-1,156

-1,436

-1,664

-1,489

-1,593

-2,116

-2,735

-4,197

-4,433

-5,522

-4,338

-4,244

-4,659

-3,894

-3,647

-3,168

-2,814

-2,719

-2,744

-2,611

-2,284

-2,405

-2,389

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

3

2

5

6

5

5

6

5

6

6

7

7

7

7

8

4

5

5

5

5

4

4

3

2

3

Amortization of right-of-use asset - operating

22

22

17

16

16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of other assets

-

-

-

-

-

-

-

-

-

60

90

89

90

89

90

60

57

56

55

47

31

-

-

-

-

Amortization of premiums and discounts on marketable securities

-

-

-

-

-

0

0

0

-2

-10

-18

-36

-55

-

-

-

-

-

-

-

-

-

-

-

-

Share-based compensation

16

27

29

45

50

58

58

60

97

119

119

119

101

-29

267

183

155

145

149

175

130

156

161

172

158

Change in operating assets and liabilities:
Other current assets

75

-142

-98

-156

-5

-167

-39

-196

-287

-251

-84

-176

74

-51

-165

-14

277

-66

-61

-225

139

-82

-87

-296

251

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

129

0

296

7

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

698

Accounts payable

-293

283

-82

-11

-2

13

-188

-203

-14

-612

170

93

-234

193

257

11

380

-264

31

-54

-144

430

-360

173

-45

Accrued compensation and employee benefits

60

-29

44

-92

56

-34

50

-105

-518

564

52

-100

-478

557

62

-52

-517

555

-88

79

-206

230

-42

30

-348

Accrued expenses and other liabilities

-99

-379

158

126

-32

-63

52

-91

-196

-397

-81

144

527

-394

16

407

-32

-33

205

67

-43

-110

74

-29

-117

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-1

0

-2

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-4,344

-3,842

-3,736

-3,526

-3,883

-2,620

-2,402

-2,399

-3,113

-1,879

-2,077

-1,763

-3,687

Net cash used in operating activities

-1,686

-1,158

-887

-1,190

-1,566

-1,343

-1,576

-2,254

-3,071

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Purchases of property and equipment

3

-

-

-

-

0

3

0

1

-

-

-

-

4

6

1

1

2

2

5

2

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

3,432

497

1,542

0

3,042

12,261

5,201

-

-

-

-

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

0

0

0

3,050

4,750

2,500

6,600

4,550

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-3

-

-

-

-

0

-3

0

3,049

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

3,008

3,148

-2,548

-11,812

-5,202

-2

-2

-5

-2

-

-

-

-

Proceeds from the issuance of common stock

-

0

764

3,436

3,081

0

0

0

3,532

36

4,231

2,074

210

-

-

-

-

-

-

-

-

0

0

20

9,018

Common stock offering costs

-

4

81

170

117

0

0

1

116

29

198

116

105

-

-

-

-

-

-

-

-

-

-

-

-

Repayment of principal on vendor finance agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

55

83

55

0

51

77

51

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

105

-

-

-

-

-58

-200

34,306

-55

-2

-51

-57

8,133

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-1,231

-694

-6,284

-15,338

-9,085

-2,680

-2,604

31,902

-3,170

-

-

-

-

Net cash provided by financing activities

-

-122

568

3,150

2,964

-105

0

-207

3,416

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-1,689

-

-

-

1,398

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-2,461

3,394

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,825

4,446

Supplemental cash flow information:
Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

2

1

0

1

1

1

Income tax refund received

-

16

42

27

82

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of noncash investing and financing transactions:
Vendor finance agreement

408

-

-115

-116

349

-

0

-206

311

-

-

-170

256

-

-

-

-

-

-

-83

138

-

-

-77

128

Proceeds receivable from the issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-209

11

-

-

-

-

-

-

-

-

-

-

-

-

Common stock offering costs accrued but not yet paid

-

-

-54

4

64

-

-

-

1

-

-

35

47

-

-

-

-

-

-

-

-

-

-

-

-

Leased assets obtained in exchange for operating lease liabilities, upon adoption and extension

49

33

0

0

60

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in unrealized loss on marketable securities

-

-

-

-

-

0

0

0

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in unrealized loss on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

10

-13

-19

7

6

-

-

-

-

-

-

-

-

Payable for purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,009

-

-

-

-

-

-

-

-